Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TaiGen Biopharmaceuticals Holdings has the GF Score of 59, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes TaiGen Biopharmaceuticals Holdings
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
TaiGen Biopharmaceuticals Holdings GF Score Related Terms
ROCO:4157 vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's GF Score distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's GF Score falls into.
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a GF Score of 59 as of Jul. 18, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. This is near median its historical median of 57.00. Over the past decade, TaiGen Biopharmaceuticals Holdings' GF Score has ranged from 20.00 to 77.00.
Is TaiGen Biopharmaceuticals Holdings' GF Score too high?
TaiGen Biopharmaceuticals Holdings' current GF Score of 59 is near median its 10-year median of 57.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 77.00. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' GF Score compare to VRTX and REGN?
TaiGen Biopharmaceuticals Holdings' GF Score of 59 can be compared against companies in the Biotechnology industry. Historically, TaiGen Biopharmaceuticals Holdings' own GF Score has ranged from 20.00 to 77.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. TaiGen Biopharmaceuticals Holdings's current GF Score is 59, which is near median its own 10-year median of 57.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.18, compared to a current price of NT$8.43 — trading 75.3% below its estimated fair value. The current GF Score is 59, which is near median its 10-year median of 57.00. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current GF Score is 59 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$8.43 is trading 75.3% below its estimated GF Value™ of NT$34.18.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.
Key valuation signals for ROCO:4157:
GF Score: 59 (near median its 10-year median of 57.00)
GF Value™: NT$34.18 vs. price of NT$8.43 (75.3% below fair value)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Business Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score
Get the complete analysis for ROCO:4157
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
